Table 1.
Characteristics of the two cohorts of patients included in the study.
| Investigated Variables | Categories | Vaccination Cohort (SARS-CoV-2 Negative) |
SARS-CoV-2 Positive Cohort (Not Vaccinated) |
p-Value |
|---|---|---|---|---|
| Total, N (%) | 1256 (82.2) | 272 (17.8) | ||
| Age, median (IQR) | 43 (30–54) | 43 (31–51) | 0.62 | |
| Gender, N (by column %) | ||||
| - F | 688 (54.8) | 115 (42.3) | <0.001 * | |
| - M | 568 (45.2) | 157 (57.7) | ||
| Days after first dose of vaccination or COVID positivity, median (IQR) | 37 (34–41) | 40 (32–49) | 0.13 | |
| IgG (AU/mL) median (IQR) | 342 (259–400) | 48.9 (25.6–92.1) | <0.001 | |
| Worst clinical presentation, IgG median (IQR) | ||||
| - Asymptomatic, Mild | - | 46.4 (24–88.3) | ||
| - Moderate | - | 90.5 (53.7–92.7) | ||
| - Severe, Critical | - | 101.2 (22.3–191.7) | ||
| IgG (AU/mL), N (by column %) |
||||
| -Seronegative | 2 (0.2) | 28 (10.3) | <0.001 * | |
| - 12 to 15 | 0 (0) | 10 (3.7) | ||
| - >15 to 50 | 1 (0.1) | 101 (37.1) | ||
| - 51 to 100 | 7 (0.6) | 77 (28.7) | ||
| - 101 to 150 | 53 (4.2) | 25 (9.2) | ||
| - 151 to 200 | 90 (7.2) | 15 (5.5) | ||
| - 201 to 250 | 130 (10.3) | 6 (2.2) | ||
| - 251 to 300 | 184 (14.6) | 2 (0.7) | ||
| - 301 to 350 | 193 (15.4) | 1 (0.4) | ||
| - 351 to inf | 596 (47.4) | 6 (2.2) |
* The p-value refers to a statical difference within the entire group.